How to Find a Supplement Manufacturer: 5 Steps (USA, 2026)

A “supplement manufacturer” covers four different businesses. Our directory tracks 27 contract supplement manufacturers, 14 private-label supplement manufacturers, 22 full-service partners and 11 format specialists: the type decides your MOQ, timeline and who owns the formula:

• Private label: you brand a stock formula. Fastest launch (weeks), lowest minimums, least differentiation. Best for a first SKU or testing demand.
• Contract manufacturing: a maker builds your formula to spec. Your IP, higher minimums, typically 10–12 weeks from signed specs. Best for a differentiated product.
• Full-service / turnkey: formulation through fulfillment under one roof. Best when you lack in-house R&D, label and fulfillment. You pay a margin premium for one partner accountable end to end.
• Specialist: one format done well. Best when format risk dominates, for example gummy texture and stability or vegetarian softgel encapsulation.

Many brands do both: stock SKUs first for cash flow, signature custom formulas second.

Formats are the real constraint. In our 74-maker directory, 56 handle capsules but only 29 run gummies and 22 run softgels. Gummies need molding lines and softgels need rotary-die encapsulation lines that generalist powder plants often subcontract out. If your hero SKU is a gummy or softgel, shortlist makers that run that format in-house first:

• Gummy supplement manufacturers (29). Highest tooling cost, longest lead times of any format.
• Softgel supplement manufacturers (22). Confirm vegetarian capability explicitly; it is a separate line.
• Protein powder makers (15). A volume game: blending consistency and flavor systems matter most.
• Probiotic makers (14). Demand strain documentation and CFU-through-expiry guarantees.

Geography comes second: US production means faster freight, walk-in audits, and a US-made label claim. Shortlist on certifications and MOQ first, zip code second. Then compare inside supplement manufacturers in the USA and the state hubs (California, Florida, Texas, New Jersey).

27 of 74 makers trace to an independent registry entry. The other 47 rest on maker-hosted PDFs or unverified claims (live numbers). Verify in this order:

• FDA facility registration. Facilities register with FDA; they are not “FDA approved.” Anyone claiming approval for a dietary-supplement facility is misrepresenting. Move on.
• GMP scope in a public registry. “GMP compliant” is a self-claim; “GMP certified” means a third party (NSF, NPA, UL) audited the facility. Look the maker up in the NSF 455-2 directory or USDA Organic Integrity Database under its exact legal name and address. Names rarely match marketing names.
• Cert documents on the maker site. A cert PDF or audit letter hosted by the maker (like BNI Pure's NSF 455-2 certificate for its Chatsworth facility) is meaningful but one rung below a registry entry.
• Batch COAs from an ISO 17025 lab. Ask for a recent finished-product COA, not just a raw-material spec. If a maker cannot produce one, that is disqualifying.
• MOQ and lead time in writing. 70 of 74 makers in our directory publish no MOQ numbers. That is industry-normal, not a red flag. But get yours in writing before formulation work starts.
• Street address and which facility runs your format. Multi-site makers (e.g. Vitaquest's four NJ facilities) may hold different scopes per site. Confirm yours.

Evidence grading rubric: the paper-trail standard every profile on this site is held to.

Send the same one-page spec to 3–5 makers and score the responses against each other. Include: format and count per bottle, key actives with doses, stock vs custom formula, packaging (bottle, pouch, stick pack), target MOQ and reorder cadence, label-compliance review ownership, testing depth (identity, potency, micro, heavy metals), and timeline.

Expect custom work to run 10–12 weeks from signed specs; gummy commercial runs add 4–8 weeks after pilot approval; liquid reorders typically turn in 6–8 weeks. Quotes that promise custom gummies in three weeks deserve skepticism, not celebration.

Send the same one-pager to 3–5 makers via the quote form and score replies side-by-side.

Normal, not disqualifying:

• No published MOQ (70 of 74 makers). Quote path only is industry standard.
• City-level address only. Common. Kill any maker that won't name the producing site before you sign specs.
• Stock formulas shared across brands. Non-exclusive by definition; competitors can sell the same pill under another label.

Actual red flags:

• No facility address at all, or a maker that will not name the producing site.
• A broker presenting as a manufacturer. Ask who owns the encapsulation line.
• No COA available, or a COA from the maker's own lab with no third-party testing.
• “FDA approved facility” language, or pressure to skip label-compliance review.